天瑞仪器(300165) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for the third quarter reached ¥525,268,787.75, representing a 122.91% increase compared to the same period last year[4]. - The net profit attributable to shareholders was -¥13,883,941.52, a decrease of 133.59% year-on-year[4]. - The company reported a basic earnings per share of -¥0.0256, down 128.60% from the same period last year[4]. - The net profit for Q3 2021 was CNY 984,176.03, a significant decrease from CNY 19,600,254.19 in the same period last year, representing a decline of approximately 95%[32]. - The total operating profit for Q3 2021 was CNY 11,443,518.39, down from CNY 34,988,374.98 in Q3 2020, indicating a decrease of about 67%[31]. - The company experienced a total comprehensive income of CNY 984,176.03 for Q3 2021, down from CNY 19,600,254.19 in the previous year, reflecting a decline in overall financial performance[32]. Cash Flow - The cash flow from operating activities showed a significant improvement, with a net amount of -¥277,162,184.18, reflecting a 349.19% increase from the previous year[4]. - Net cash flow from operating activities was -27,716.22 million, a decline of 349.19% from -6,170.31 million, primarily due to increased procurement and operational payments related to PPP projects[13]. - The cash flow from operating activities showed a net outflow of CNY 277,162,184.18, compared to a net outflow of CNY 61,703,060.39 in the previous year, reflecting a worsening cash flow situation[35]. - The company reported a total cash inflow from financing activities of CNY 723,262,166.51, compared to CNY 276,190,326.85 in the previous year, indicating a significant increase in financing activities[36]. - The cash outflow from investing activities was CNY 509,620,687.28, up from CNY 309,015,599.95 in the same period last year, showing increased investment expenditures[35]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,314,082,791.20, an increase of 29.23% compared to the end of the previous year[4]. - Total assets increased to CNY 3,314,082,791.20 from CNY 2,564,439,469.59, showing strong growth in the company's financial position[26]. - Total liabilities rose to CNY 1,578,546,669.74, up from CNY 825,379,245.12, indicating increased leverage[27]. - The company's equity totaled CNY 1,739,060,224.47, with a decrease of CNY 482,930.39[41]. Investments and R&D - The company has seen a 153.14% increase in prepayments, totaling ¥20,988.65 million, primarily due to materials procurement[10]. - R&D expenses rose by 37.55% to 5,536.75 million from 4,025.31 million, driven by an increase in R&D projects[12]. - The company is actively developing new products, including a flu virus antigen detection kit, which has increased capitalized development expenditures by 67.96%[10]. - The company has a significant focus on research and development in biological feed and organic fertilizers, indicating a strategic shift towards sustainable products[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,884[15]. - The largest shareholder, Liu Zhaogui, holds 29.04% of the shares, totaling 144,326,306 shares[15]. - The total number of restricted shares held by executives and related parties is 202,211,509, with 171,106,061 shares still under restriction[21]. - The company reported a total of 13,634,389 restricted shares held by various counterparties, which will not be transferred within 12 months[21]. Government Subsidies and Income - The company received government subsidies related to R&D projects, contributing to an increase in deferred income by 85.21%[11]. - The company reported a decrease in government subsidy income, with other income falling by 67.16% to 38.55 million from 117.40 million[12]. Market and Product Development - The company is expanding its market presence through the sale of ecological environment monitoring instruments and laboratory analysis instruments[22]. - The company is focusing on market expansion and new product development, with specific strategies to be outlined in upcoming communications[30].